- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 429
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
Clinical trials in Atlanta, Georgia
This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Atlanta
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2038
- U.S. locations
- 242
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 189 more
- Conditions
- Atrial Fibrillation
- Interventions
- VARIPULSE Catheter, FARAWAVE Catheter
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Jonesboro, Arkansas • Fountain Valley, California • Ventura, California + 16 more
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 10 more
- Conditions
- Ovarian Cancer, Non-small Cell Lung Cancer
- Interventions
- TUB-040, Bevacizumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 10 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- TAK-411
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Atrial Fibrillation
- Interventions
- Milvexian, Apixaban, Placebo, Apixaban Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 216
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- ITI-1284 10 mg, ITI-1284 20 mg, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 21 more
- Conditions
- Breast Reconstruction, Revision Breast Reconstruction
- Interventions
- Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
- Device
- Lead sponsor
- Mentor Worldwide, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 30
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tobemstomig, Tiragolumab, Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • Atlanta, Georgia + 3 more
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Interventions
- Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 2 more
- Conditions
- Narcolepsy Type 1, Narcolepsy Type 2
- Interventions
- cleminorexton, Placebo
- Drug
- Lead sponsor
- Centessa Pharmaceuticals (UK) Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 20 more